Exenatide vs Tirzepatide

Q: Is Exenatide better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6/10) and wins in 2 of 3 categories.

Q: Is Exenatide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 46).

Q: Can I take Exenatide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Exenatide vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 6/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Tirzepatide Edges Ahead

Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Exenatide0 wins

Tirzepatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Exe6.0

Exenatide

Too few graded studiesLimited safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

6/10

Studies: 113

Meta-analyses: 24

Level: Moderate

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies64
Weight managementToo few graded studies23
Cardiovascular outcomesToo few graded studies18

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Shared outcomes (3)

Outcomes where both Exenatide and Tirzepatide have evidence — compare verdict strength side-by-side.

Weight managementToo few graded studies23Too few graded studies80
Glycemic & metabolic controlToo few graded studies64Too few graded studies53
Heart & blood pressureToo few graded studies18Too few graded studies20

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA BOXED WARNING (extended-release exenatide, Bydureon BCise): thyroid C-cell tumors. GLP-1 receptor agonists cause thyroid C-cell (medullary) tumors in rodents; human relevance is undetermined. Under that US label, contraindicated with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Immediate-release Byetta does not carry this US boxed warning. The EU marketing authorisations for Byetta and Bydureon were withdrawn on 1 January 2026 at the company’s request for commercial reasons. In Germany or Austria, discuss current availability and authorised alternatives with your prescriber. Do not stop or change your prescribed diabetes treatment on your own.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis) — a meta-analysis of GLP-1 agonists found a significantly increased cholelithiasis risk.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are common, especially early and during dose escalation.
Renal: exenatide is renally cleared — avoid in severe renal impairment (eGFR <30) and dialysis; cases of acute kidney injury have been reported, often with dehydration from GI losses.
Injection-site reactions (nodules/induration) are more common with the once-weekly depot.
Cardiovascular benefit is NOT established: the EXSCEL outcomes trial was neutral on its primary endpoint (HR 0.91; P=0.06) — unlike liraglutide, semaglutide and dulaglutide. Do not assume class-wide CV protection.
May increase hypoglycemia risk when combined with sulfonylureas or insulin (dose adjustment needed).
Largely superseded by newer, more potent GLP-1 agents — discuss alternatives with a clinician.
Avoid COMPOUNDED / grey-market exenatide: risk of dosing errors, impurities, and unapproved product. Use only pharmacy-dispensed product.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly extended-release injection (Bydureon)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Sulfonylureas and insulin (moderate)
Oral medications (general) (moderate)

and 1 more not shown

Side Effects:

NauseaVomiting / diarrheaInjection-site nodules / induration (once-weekly form)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label for extended-release exenatide, Bydureon BCise, not for immediate-release Byetta)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label for extended-release exenatide, Bydureon BCise, not for immediate-release Byetta)

Limited safetyTie

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightTirzepatide

Exenatide46/100

Tirzepatide90/100

Manage blood sugarTirzepatide

Exenatide66/100

Tirzepatide85/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Modest weight losspositive

Months

❤️ Cardiovascular: neutral primary outcomeneutral

Years

🤢 GI adverse effects (common)trade-off

Especially early / during dose escalation

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL).

N Engl J Med (2017) · Rct · n=14752

Large cardiovascular-outcomes RCT: 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease), once-weekly exenatide 2 mg vs placebo added to usual care, median 3.2 years

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1): a randomised, open-label, non-inferiority study.

Lancet (2008) · Rct · n=295

30-week open-label RCT in 295 patients with type 2 diabetes comparing once-weekly extended-release exenatide 2 mg with 10 µg twice daily

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Lancet (2013) · Rct · n=911

26-week head-to-head open-label RCT in 911 patients: once-weekly exenatide 2 mg vs once-daily liraglutide 1.8 mg added to oral therapy

All Exenatide studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Exenatide better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6/10) and wins in 2 of 3 categories.

Is Exenatide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 46).

Can I take Exenatide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Exenatide vs Semaglutide Exenatide vs Liraglutide Exenatide vs Thiamine Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Exenatide and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Exenatide details Tirzepatide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA BOXED WARNING (extended-release exenatide, Bydureon BCise): thyroid C-cell tumors. GLP-1 receptor agonists cause thyroid C-cell (medullary) tumors in rodents; human relevance is undetermined. Under that US label, contraindicated with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Immediate-release Byetta does not carry this US boxed warning. The EU marketing authorisations for Byetta and Bydureon were withdrawn on 1 January 2026 at the company’s request for commercial reasons. In Germany or Austria, discuss current availability and authorised alternatives with your prescriber. Do not stop or change your prescribed diabetes treatment on your own.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis) — a meta-analysis of GLP-1 agonists found a significantly increased cholelithiasis risk.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are common, especially early and during dose escalation.

Renal: exenatide is renally cleared — avoid in severe renal impairment (eGFR <30) and dialysis; cases of acute kidney injury have been reported, often with dehydration from GI losses.

Injection-site reactions (nodules/induration) are more common with the once-weekly depot.

Cardiovascular benefit is NOT established: the EXSCEL outcomes trial was neutral on its primary endpoint (HR 0.91; P=0.06) — unlike liraglutide, semaglutide and dulaglutide. Do not assume class-wide CV protection.

May increase hypoglycemia risk when combined with sulfonylureas or insulin (dose adjustment needed).

Largely superseded by newer, more potent GLP-1 agents — discuss alternatives with a clinician.

Avoid COMPOUNDED / grey-market exenatide: risk of dosing errors, impurities, and unapproved product. Use only pharmacy-dispensed product.

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Exenatide better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 6/10) and wins in 2 of 3 categories.

Is Exenatide or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 46).

Can I take Exenatide and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.